National Advertising Division Will Refer Willow Health to State and Federal Regulatory Authorities for its Compounded Semaglutide Product Claims
National Advertising Division Will Refer Willow Health to State and Federal Regulatory Authorities for its Compounded Semaglutide Product Claims Following a challenge brought by Novo Nordisk Inc., BBB National Programs' National Advertising Division recommended Willow Health Services, Inc. modify or discontinue health-related claims for its compounded semaglutide products. GlobeNewswire December 04, 2025 New York, NY, […]